000154659 001__ 154659
000154659 005__ 20210129213933.0
000154659 0247_ $$2Handle$$a2128/15605
000154659 037__ $$aFZJ-2014-03943
000154659 041__ $$aEnglish
000154659 1001_ $$0P:(DE-Juel1)133346$$aSchmitz, Sabine$$b0$$eCorresponding author
000154659 1112_ $$a14th International Congress of Radiation Research$$cWarsaw$$d2011-08-28 - 2011-09-01$$gICCR$$wPoland
000154659 245__ $$aChromosomal radiosensitivity of prostate cancer patients and healthy donors analysed by FISH
000154659 260__ $$c2011
000154659 300__ $$a163
000154659 3367_ $$2ORCID$$aCONFERENCE_PAPER
000154659 3367_ $$033$$2EndNote$$aConference Paper
000154659 3367_ $$2BibTeX$$aINPROCEEDINGS
000154659 3367_ $$2DRIVER$$aconferenceObject
000154659 3367_ $$2DataCite$$aOutput Types/Conference Paper
000154659 3367_ $$0PUB:(DE-HGF)8$$2PUB:(DE-HGF)$$aContribution to a conference proceedings$$bcontrib$$mcontrib$$s1507882391_2859
000154659 520__ $$aBackground: It is known that about 10 % of cancer patients show severe clinical side effects during and after radiotherapy due to enhanced sensitivity to ionizing ra-diation. Identification of those radiosensitive individuals by an in vitro assay before onset of treatment would be of great impact for successful radiotherapy.In this study we compared the radiosensitivity of the chromosomes 2, 11 and 17 in prostate cancer patients with and without severe side effects after radiotherapy and in age-matched healthy donors (control cohort). The chromosomal radiosensitivity of peripheral blood lymphocytes (PBL) of radiotherapy patients was used as predictive parameter for clinical side effects.Material und Methods: Each cohort consisted of at least 10 donors. PBL were irra-diated ex vivo with 0.5, 1 und 2 Gy (Cs-137 -rays) in the G0-Phase of the cell cycle. We analyzed the radiosensitivity of the chromosomes 2, 11 and 17 by scoring of 100 FISH painted metaphases for each dose point. Statistical analyses were performed by non-parametric Mann-Whitney test, by test of variances (ANOVA) and Chi-square goodness-of-fit test at a significance level of 0.05. Results: Analysis of the overall aberration yield revealed no significant differences between any donor groups. However, variance analyses showed significant differ-ences between the patient’s cohort and healthy donors for chromosomes 11 and 17 for all doses analyzed. In contrast, this was not true for chromosome 2. Furthermore, good correlations between chromosomes sizes (DNA content) and aberration yield were found.Conclusion: The cohort of prostate cancer patients can be distinguished from healthy donors due to variances of the aberration yields of the chromosomes 11 and 17. These chromosomes might be potential cytogenetic biomarkers for prostate can-cer patients in clinical studies. Funded by Dr. Erich-Schmitt -Foundation
000154659 536__ $$0G:(DE-HGF)POF2-899$$a899 - ohne Topic (POF2-899)$$cPOF2-899$$fPOF I$$x0
000154659 65027 $$0V:(DE-MLZ)SciArea-160$$2V:(DE-HGF)$$aBiology$$x0
000154659 7001_ $$0P:(DE-HGF)0$$aBrzozowska, Kinga$$b1
000154659 7001_ $$0P:(DE-HGF)0$$aPinkawa, M.$$b2
000154659 7001_ $$0P:(DE-HGF)0$$aEble, M.$$b3
000154659 7001_ $$0P:(DE-Juel1)133469$$aKriehuber, Ralf$$b4
000154659 8564_ $$uhttps://juser.fz-juelich.de/record/154659/files/Abstract%20Schmitz%20ICRR%202011%20Warschau.pdf$$yOpenAccess
000154659 8564_ $$uhttps://juser.fz-juelich.de/record/154659/files/Abstract%20Schmitz%20ICRR%202011%20Warschau.gif?subformat=icon$$xicon$$yOpenAccess
000154659 8564_ $$uhttps://juser.fz-juelich.de/record/154659/files/Abstract%20Schmitz%20ICRR%202011%20Warschau.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000154659 8564_ $$uhttps://juser.fz-juelich.de/record/154659/files/Abstract%20Schmitz%20ICRR%202011%20Warschau.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000154659 8564_ $$uhttps://juser.fz-juelich.de/record/154659/files/Abstract%20Schmitz%20ICRR%202011%20Warschau.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000154659 8564_ $$uhttps://juser.fz-juelich.de/record/154659/files/Abstract%20Schmitz%20ICRR%202011%20Warschau.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000154659 909CO $$ooai:juser.fz-juelich.de:154659$$pdnbdelivery$$pVDB$$pdriver$$popen_access$$popenaire
000154659 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133346$$aForschungszentrum Jülich GmbH$$b0$$kFZJ
000154659 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133469$$aForschungszentrum Jülich GmbH$$b4$$kFZJ
000154659 9132_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000154659 9131_ $$0G:(DE-HGF)POF2-899$$1G:(DE-HGF)POF2-890$$2G:(DE-HGF)POF2-800$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000154659 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000154659 920__ $$lyes
000154659 9201_ $$0I:(DE-Juel1)S-US-20090406$$kS-US$$lSicherheit und Strahlenschutz, Umgebungsüberwachung,Strahlenbiologie$$x0
000154659 980__ $$acontrib
000154659 980__ $$aVDB
000154659 980__ $$aUNRESTRICTED
000154659 980__ $$aI:(DE-Juel1)S-US-20090406
000154659 9801_ $$aFullTexts